The Administrative Core will be responsible for providing scientific administration and coordination, fiscal oversight and administrative support. To ensure optimal cooperation and communication, the Core will coordinate meetings at least every three weeks among the Program Project members, who are located at Children's Hospital Boston, the Dana Farber Cancer Institute, the CBER/FDA and Consejo Superior de Investigaciones Cientificas, CSIC, Madrid, using Web based media. The Administrative Core takes on added importance because of the geographic distance between the Program Project investigators, and will provide effective communication services. Due to special circumstances, the Administrative Core will also administrate and oversee funds allocated for postdoctoral fellows and supplies to one ofthe collaborators, Dr. Gerardo Kaplan at the CBER/FDA. This administrative activity includes purchasing supplies for the CBER/FDA site, as well as coordinating the hiring of personnel working at the CBER/FDA site, through the Children's Hospital Boston. Children's Hospital Boston and Dale T. Umetsu are responsible for the application and for collaborative research activities described.

Public Health Relevance

The Program Project will focus on inflammatory diseases including asthma and allergy as well as, and study the mechanisms of immune regulation. We will determine how a newly discovered family of genes called TIMs, regulate immune responses that cause these clinical problems. These genes have remarkably novel functions that affect immunity, and could lead to new therapies for asthma, allergy and autoimmunity

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI054456-09
Application #
8507124
Study Section
Special Emphasis Panel (ZAI1-RRS-I)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$156,523
Indirect Cost
$46,144
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Chuang, Ya-Ting; Leung, Krystle; Chang, Ya-Jen et al. (2018) A natural killer T-cell subset that protects against airway hyperreactivity. J Allergy Clin Immunol :
Chaudhri, Apoorvi; Xiao, Yanping; Klee, Alyssa N et al. (2018) PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface. Cancer Immunol Res 6:921-929
Costafreda, Maria Isabel; Kaplan, Gerardo (2018) HAVCR1 (CD365) and Its Mouse Ortholog Are Functional Hepatitis A Virus (HAV) Cellular Receptors That Mediate HAV Infection. J Virol 92:
Kamphorst, Alice O; Wieland, Andreas; Nasti, Tahseen et al. (2017) Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355:1423-1427
Santiago, César; Mudgal, Gaurav; Reguera, Juan et al. (2017) Allosteric inhibition of aminopeptidase N functions related to tumor growth and virus infection. Sci Rep 7:46045
Morales-Kastresana, Aizea; Telford, Bill; Musich, Thomas A et al. (2017) Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. Sci Rep 7:1878
Foks, Amanda C; Engelbertsen, Daniel; Kuperwaser, Felicia et al. (2016) Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Arterioscler Thromb Vasc Biol 36:456-65
Brauner, Eran; Gunda, Viswanath; Vanden Borre, Pierre et al. (2016) Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget 7:17194-211
Kim, Hye Young; Umetsu, Dale T; Dekruyff, Rosemarie H (2016) Innate lymphoid cells in asthma: Will they take your breath away? Eur J Immunol 46:795-806
Baumeister, Susanne H; Freeman, Gordon J; Dranoff, Glenn et al. (2016) Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol 34:539-73

Showing the most recent 10 out of 46 publications